Montag, 27.04.2026, Calendar Week 18, 117. day of the year, 248 days remaining until EoY.

Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.

Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US0465131078

Filter zurücksetzen

Do you already know our new terminal view? Click here.

FIGI: -

ATRA

Atara Biotherapeutics, Inc.

GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH

NAME

Atara Biotherapeutics, Inc.

ISIN

US0465131078

TICKER

ATRA

MIC

XNAS

REUTERS

ATRA.OQ

BLOOMBERG

ATRA US

Mo., 23.02.2026 Atara Biotherapeutics

Newsfeed

Atara Biotherapeutics Provides a Business Update | Atara Biotherapeutics, Inc.

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel) | Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress | Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Changes to Its Board of Directors | Atara Biotherapeutics, Inc.

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) | Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease | Atara Biotherapeutics, Inc.

Pierre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. | Atara Biotherapeutics, Inc.

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®) | Atara Biotherapeutics, Inc.

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors | Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress | Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Pricing of $16 Million Offering | Atara Biotherapeutics, Inc.

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) | Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress | Atara Biotherapeutics, Inc.

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws | Atara Biotherapeutics, Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA | Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Atara Biotherapeutics, Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA | Atara Biotherapeutics, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA | Atara Biotherapeutics, Inc.

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm | Atara Biotherapeutics, Inc.

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm | Atara Biotherapeutics, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA | Atara Biotherapeutics, Inc.

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219 | Atara Biotherapeutics, Inc.

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel) | Atara Biotherapeutics, Inc.

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference | Atara Biotherapeutics, Inc.

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference | Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress | Atara Biotherapeutics, Inc.

Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 | Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Atara Biotherapeutics, Inc.

Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference | Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces $36 Million Registered Direct Offering | Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update | Atara Biotherapeutics, Inc.

XFRA : CAPITAL ADJUSTMENT INFORMATION - 20.06.2024 - US0465131078 | Atara Biotherapeutics, Inc.

XFRA : INSTRUMENT_SUSPENSION - US0465131078 | Atara Biotherapeutics, Inc.

XFRA : CAPITAL ADJUSTMENT INFORMATION - 20.06.2024 - US0465131078 | Atara Biotherapeutics, Inc.

ATRA INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Atara Biotherapeutics, Inc. | Atara Biotherapeutics, Inc.